Loading
Life sciences · Journal article
Cancers · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Long-term survivors of hormone receptor-positive breast cancer, prostate adenocarcinoma, and renal cell carcinoma may develop metastatic disease years after treatment. Vertebral involvement can cause instability and neurologic injury, but first late vertebral recurrence is poorly measured because studies frequently combine vertebral and other skeletal events. This narrative review synthesizes selected recurrence cohorts, experimental studies, randomized trials, and professional guidance. It distinguishes first late distant recurrence, biochemical recurrence, and progression of established metastatic disease; examines proposed mechanisms of marrow persistence; and considers detection and management. Late systemic risk is established, particularly in estrogen receptor-positive breast cancer, but vertebral-specific incidence remains uncertain. Niche studies provide biological plausibility without demonstrating a uniquely vertebral dormancy process. MRI assesses local marrow and neural involvement, while tumor-appropriate PET/CT maps disease distribution; tracer biology influences detection. Relevant trials address different questions: spinal MRI screening in metastatic castration-resistant prostate cancer, treatment of identified high-risk bone lesions, or metastasis-directed therapy in oligorecurrent disease. None establishes scheduled spine MRI for asymptomatic disease-free survivors. Concerning symptoms and tumor-specific recurrence signals warrant timely diagnostic evaluation. Identified lesions require assessment of neurologic compression, oncologic options, mechanical stability, and systemic status. Prospective cohorts and intervention studies should measure vertebral-specific events, function, quality of life, and downstream harms before risk-defined screening is recommended.